Trial · NCT04410328
Aggrenox To Treat Acute Covid-19
NCT04410328, Phase 3, Completed, Rutgers, The State University of New Jersey; results first posted 2025-02-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Aggrenox To Treat Acute Covid-19. Trials, record NCT04410328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04410328
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aggrenox To Treat Acute Covid-19
- NCT number
- NCT04410328
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 98 participants, actual
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- Covid19
- Interventions
- Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
- First posted
- 2020-06-01
- Last updated
- 2025-02-21
- Results first posted
- 2025-02-21
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Covid (Coronavirus Disease-19) Ordinal Scale | 15 days | Change in composite COVID ordinal scale from day 1 to 14. Ordinal scale: 1) not hospitalized with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring oxygen; 4) hospitalized, requiring oxygen; 5) hospitalized, requiring high-flow oxygen therapy, or noninvasive ventilation; 6) hospitalized, requiring invasive ventilation; 7) ventilation plus additional organ support such as pressors, renal replacement therapy and ECMO and 8) death. COVID Ordinal Scale ranges from 1 to 8, with score 1 on the scale corresponds to an ambulatory patient with minimal symptoms and score 8 on the scale corresponds to death. |
| Secondary | Mortality | 14 days | All-cause mortality assessed on day 14. |
| Secondary | Mortality | 28 days | All-cause mortality assessed on day 28. |
| Secondary | Inflammatory Marker Between Baseline and 7 Days | Baseline and 7 days | Change in marker D-dimer |
| Secondary | COVID Ordinal Scale | 28 days | COVID ordinal scale |
| Secondary | Number of Participants Not Requiring Supplemental Oxygen | 28 days | number of participants who received supplemental oxygen or those with supplemental oxygen-free days |
| Secondary | Invasive-ventilator | 28 days | Number of participants who were invasive-ventilator free |
| Secondary | ICU Stay | 28 days | Number of participants admitted to ICU |
| Secondary | Inflammatory Marker | Baseline and 7 days | Increase in marker Ferritin |
| Secondary | Inflammatory Marker | Baseline and 7 days | Increase in marker C-reactive protein |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Covid (Coronavirus Disease-19) Ordinal Scale | 15 days | score on a scale | MEDIAN | |
| SECONDARY | Mortality | 14 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Mortality | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Inflammatory Marker Between Baseline and 7 Days | Baseline and 7 days | ng/mL | MEDIAN | |
| SECONDARY | COVID Ordinal Scale | 28 days | scores on a scale | MEDIAN | |
| SECONDARY | Number of Participants Not Requiring Supplemental Oxygen | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Invasive-ventilator | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | ICU Stay | 28 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Inflammatory Marker | Baseline and 7 days | ug/L | MEDIAN | |
| SECONDARY | Inflammatory Marker | Baseline and 7 days | ug/L | MEDIAN |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Covid (Coronavirus Disease-19) Ordinal Scale | Participants Receiving Dipyridamole and Aspirin | 2.3 | Standard Deviation 1.8 | score on a scale | |
| Covid (Coronavirus Disease-19) Ordinal Scale | Participants Receiving Standard of Care | 2.1 | Standard Deviation 2.0 | score on a scale | |
| Mortality | Participants Receiving Dipyridamole and Aspirin | 2 | Participants | ||
| Mortality | Participants Receiving Standard of Care | 2 | Participants | ||
| Mortality | Participants Receiving Dipyridamole and Aspirin | 3 | Participants | ||
| Mortality | Participants Receiving Standard of Care | 5 | Participants | ||
| Inflammatory Marker Between Baseline and 7 Days | Participants Receiving Dipyridamole and Aspirin | -197.5 | Inter-Quartile Range -2425.0 to 366.0 | ng/mL | |
| Inflammatory Marker Between Baseline and 7 Days | Participants Receiving Standard of Care | 114 | Inter-Quartile Range -1408.0 to 240.0 | ng/mL | |
| COVID Ordinal Scale | Participants Receiving Dipyridamole and Aspirin | 3 | Inter-Quartile Range 2 to 4 | scores on a scale | |
| COVID Ordinal Scale | Participants Receiving Standard of Care | 3 | Inter-Quartile Range 2 to 3 | scores on a scale |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants Receiving Dipyridamole and Aspirin | 49 | |
| Overall Study | STARTED | Participants Receiving Standard of Care | 49 | |
| Overall Study | COMPLETED | Participants Receiving Dipyridamole and Aspirin | 49 | |
| Overall Study | COMPLETED | Participants Receiving Standard of Care | 49 | |
| Overall Study | NOT COMPLETED | Participants Receiving Dipyridamole and Aspirin | 0 | |
| Overall Study | NOT COMPLETED | Participants Receiving Standard of Care | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | death | Infections and infestations | Participants Receiving Dipyridamole and Aspirin | 5 | 49 | |
| serious | death | Infections and infestations | Participants Receiving Standard of Care | 7 | 49 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants Receiving Dipyridamole and Aspirin | 5 | 49 |
| Total, all-cause mortality | Participants Receiving Standard of Care | 7 | 49 |
| Total, other adverse events | Participants Receiving Dipyridamole and Aspirin | 0 | 49 |
| Total, other adverse events | Participants Receiving Standard of Care | 0 | 49 |
| Total, serious adverse events | Participants Receiving Dipyridamole and Aspirin | 5 | 49 |
| Total, serious adverse events | Participants Receiving Standard of Care | 7 | 49 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: ICU Stay | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Invasive-ventilator | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: deaths from any cause | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Number of Participants Not Requiring Supplemental Oxygen | Trial comparisons |
| Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04410328
GET https://conductscience.org/api/trials/v1/NCT04410328/registered